The advent of CRISPR as a gene editing tool continues to revolutionize drug discovery and development.
The routine application of human pluripotent stem cells and their derivatives in regenerative medicine and innovative drug discovery will require the constant supply of high cell numbers in consistent, high quality.
This application note details the suitability of Eppendorf BioBLU 0.3c Single-Use Vessels controlled by a DASbox Mini Bioreactor System for the expansion of human bone marrow-derived mesenchymal stem cells on microcarriers.
A look at some drug discovery challenges in details and what solutions could lead to better science and faster insights to action.
The coming years will be an exciting era in genetic research as we discover new biological mechanisms and functions for noncoding RNAs. Our improved understanding of this class of genes should provide insight into novel treatments for cancers.
By delivering significantly more data than traditional Sanger-based sequencing methods, NGS opens a range of possibilities for the analysis of diverse DNA and RNA populations.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective treatment for patients with high risk and relapsed hematologic malignancies. When donor T cells recognize the host as foreign, they induce an immune response against the host and may cause life-threatening graft-versus-host disease (GvHD), a major complication of allo-HSCT.
The biological properties of IgM antibodies make them very effective vehicles for in vitro diagnostics and therapeutics. However, purification of IgM antibodies is far more difficult than that for the more common IgG antibodies due to their complex structural and biochemical characteristics. Furthermore, the commonly available affinity chromatography supports (Protein A and Protein G) have little or no binding capacity for IgM.
Cell therapy, gene therapy, and RNA-based therapies. Right now, those are the classes of therapies we’re considering novel. If you look at it historically, ten years ago, recombinant proteins and monoclonal antibodies would have been novel therapies, but now they’ve become very much standardized. So now that bar has moved a little bit, and the novel therapies are really cell and gene therapies, and to a certain extent the RNA therapies.
